Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 4
2016 4
2017 6
2018 6
2019 5
2020 4
2021 7
2022 6
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Fischer Maranta A, Läubli H, Hottinger AF, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobagyi T, Held L, Weller M, Wirsching HG. Mastall M, et al. Among authors: migliorini d. BMC Cancer. 2024 Jan 15;24(1):82. doi: 10.1186/s12885-023-11797-z. BMC Cancer. 2024. PMID: 38225589 Free PMC article.
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W, Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K, Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM. Bagley SJ, et al. Among authors: migliorini d. Nat Cancer. 2024 Mar;5(3):517-531. doi: 10.1038/s43018-023-00709-6. Epub 2024 Jan 12. Nat Cancer. 2024. PMID: 38216766 Clinical Trial.
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.
Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, Fournier N, Torchia B, Martinez Bedoya D, Davanture S, Fernández-Vaquero M, Fan C, Janzen J, Mohammadzadeh Y, Genolet R, Mansouri N, Wenes M, Migliorini D, Heikenwalder M, De Palma M. Ghasemi A, et al. Among authors: migliorini d. Nat Cancer. 2024 Feb;5(2):240-261. doi: 10.1038/s43018-023-00668-y. Epub 2023 Nov 23. Nat Cancer. 2024. PMID: 37996514 Free PMC article.
Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma.
Bassot A, Dragic H, Haddad SA, Moindrot L, Odouard S, Corlazzoli F, Marinari E, Bomane A, Brassens A, Marteyn A, Hibaoui Y, Petty TJ, Chalabi-Dchar M, Larrouquere L, Zdobnov EM, Legrand N, Tamburini J, Lincet H, Castets M, Yebra M, Migliorini D, Dutoit V, Walker PR, Preynat-Seauve O, Dietrich PY, Cosset É. Bassot A, et al. Among authors: migliorini d. Cell Death Dis. 2023 Sep 25;14(9):630. doi: 10.1038/s41419-023-06117-z. Cell Death Dis. 2023. PMID: 37749143 Free PMC article.
Reductive carboxylation epigenetically instructs T cell differentiation.
Jaccard A, Wyss T, Maldonado-Pérez N, Rath JA, Bevilacqua A, Peng JJ, Lepez A, Von Gunten C, Franco F, Kao KC, Camviel N, Martín F, Ghesquière B, Migliorini D, Arber C, Romero P, Ho PC, Wenes M. Jaccard A, et al. Among authors: migliorini d. Nature. 2023 Sep;621(7980):849-856. doi: 10.1038/s41586-023-06546-y. Epub 2023 Sep 20. Nature. 2023. PMID: 37730993
The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D, de Bono J, Alimonti A. Pernigoni N, et al. Among authors: migliorini d. Nat Rev Urol. 2023 Dec;20(12):706-718. doi: 10.1038/s41585-023-00795-2. Epub 2023 Jul 25. Nat Rev Urol. 2023. PMID: 37491512 Review.
ChatGPT in glioma adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board?
Haemmerli J, Sveikata L, Nouri A, May A, Egervari K, Freyschlag C, Lobrinus JA, Migliorini D, Momjian S, Sanda N, Schaller K, Tran S, Yeung J, Bijlenga P. Haemmerli J, et al. Among authors: migliorini d. BMJ Health Care Inform. 2023 Jun;30(1):e100775. doi: 10.1136/bmjhci-2023-100775. BMJ Health Care Inform. 2023. PMID: 37399360 Free PMC article.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Clinical Trial.
53 results